Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMAGLIO: Multimodal Imaging in Recurrent Glioblastoma
NCT02841332Terminated
- Sponsor
- Centre hospitalier universitaire de Toulouse
- Start
- May 2013
- Primary completion
- Sep 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Open-label trial of bevacizumab in glioblastoma (GBM), sponsored by Centre hospitalier universitaire de Toulouse. Primary endpoints: Detection capacity of patient clinical status in imagery with F-MISO as assessed by tomography with emission of positron at 15 days and Detection capacity of patient clinical status in imagery with F-MISO as assessed by Perfusion magnetic resonance imagery at 15 days. Started May 2013; status: terminated.
02
Drugs
bevacizumab
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT02841332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02841332.